Gryphon International Investment’s Charles River Laboratories CRL Stock Holding History

Gryphon International Investment’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$539K	Buy	+1,305	New	+$542K	1.84%	3

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Gryphon International Investment's CRL Position: Q3 2021 in Review

Gryphon International Investment opened a new position in Charles River Laboratories (CRL) in Q3 2021: 1,305 shares worth $539K. The stake represents 1.84% of the portfolio and ranks #3 among its holdings.

677 funds tracked by Wall St. Rank hold CRL as of Q3 2021.

Gryphon International Investment held 1,305 shares of Charles River Laboratories worth $539K as of Q3 2021.
Charles River Laboratories was a new Gryphon International Investment position in Q3 2021.
Charles River Laboratories made up 1.84% of Gryphon International Investment's portfolio in Q3 2021, its #3 holding.
677 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2021.

Based on Gryphon International Investment's 13F filing for Q3 2021, filed 9 Nov 2021.